Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5166MR)

This product GTTS-WQ5166MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5166MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6788MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ14432MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10435MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ14907MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8161MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ15745MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ12248MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ9876MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW